Eric Rowinsky

Chief Medical Officer

Dr. Rowinsky serves as Chief Medical Officer at Mitra Biotech.

Dr. Rowinsky’s professional focus is on the development and registration of anticancer therapeutics and impactful diagnostics. Dr. Rowinsky serves as an Executive Director and President at RGenix, a life sciences company focused on discovering new cancer targets using microRNA. Dr. Rowinsky also has purview for clinical development and regulatory affairs. Additionally, Dr. Rowinsky serves as Chief Scientific Officer of Clearpath Development Co., which rapidly advances development stage therapeutic assets to pre-defined human Proof-of-Concept milestones. From 2012 to 2015, Dr. Rowinsky was the Head of Research and Development, Chief Medical Officer, and Executive Vice President of Stemline Therapeutics. In 2010, Dr. Rowinsky co-founded Primrose Therapeutics and became its Chief Executive Officer until it was acquired by Eli Lilly in 2011. From 2004 to 2010, he served as Chief Medical Officer and Executive Vice President of Clinical Development and Regulatory Affairs of ImClone Systems Incorporated, a life sciences company focused on monoclonal antibodies; his team was responsible for development plans that resulted in the regulatory approval of cetuximab and ramucirumab in several indications, as well as nectumumab, and olaratumab. Previous to that, he held several positions at the Cancer Therapy & Research Center’s Institute of Drug Development, including Director of the Institute and SBC Endowed Chair for Early Drug Development. Prior to that, he served as Clinical Professor of Medicine in the Division of Medical Oncology at the University of Texas Health Science Center at San Antonio and as Associate Professor of Oncology at the Johns Hopkins University School of Medicine.

Dr. Rowinsky is a member of the board of directors of Biogen Idec, Navidea (Board Chairman), and Fortress Biosciences, all of which are public life sciences companies. He has also served as a director of BIND Therapeutics, a public life science company.

Dr. Rowinsky has authored more than 310 peer-reviewed manuscripts, serves as an editor of several cancer journals, and has played integral roles in the development and registration of several other commonly used anticancer therapeutics such as paclitaxel, docetaxel, irinotecan, topotecan, lapatinib, erlotinib, temsirolumus, and panitumumab.

 

Bitnami